Deliver Your News to the World

Cordis Corporation Announces Activities At EuroPCR 2007


Cordis to introduce clinical data, innovative products, professional education opportunities and new European initiative to establish company as ’partner of choice’ of cath labs

Cordis Corporation will present late-breaking clinical data, new products and a wide-range of professional education opportunities at EuroPCR 2007, which will take place in Barcelona, Spain from May 22 to 25. The premier European conference for revascularisation will also serve as backdrop for Cordis to introduce “CathLab Cubed,” a multi-faceted initiative to support catheterisation laboratories in Europe, the Middle East and Asia.

“The CathLab Cubed concept will be central to Cordis’ presence at EuroPCR. It is built around the company’s commitment to develop and offer interventional cardiologists and cath lab teams a comprehensive portfolio of products; ready access to clinical evidence to advance understanding and support their decisions; and educational, knowledge-sharing and training opportunities through the Cordis® Cardiac & Vascular Institute™,” said Staffan Ternstrom, president, Cordis in Europe, the Middle East and Africa. “Through a combination of these elements we aim to help cath lab teams to achieve the optimum patient outcomes and to establish Cordis as their partner of choice.”

Scientific Evidence

The EuroPCR Scientific Program will contribute to growing the extensive body of clinical evidence assessing the safety and efficacy of Cordis’ interventional vascular technologies. The late-breaking clinical trial program will include three-year results in the diabetic patient population subgroup from the ARTS II Study, which compares the CYPHER® Sirolimus-eluting Coronary Stent versus bypass surgery in patients with multivessel coronary disease. In addition, investigators will present preliminary data at 36 and 48 months from the SIROCCO II Trial, a double-blind, randomized prospective study involving a sirolimus-eluting stent versus a bare metal stent and assessing the long-term outcomes in superficial femoral artery (SFA) stenting.

New Products

EuroPCR will also mark the European launch of the AVIATOR™ Plus Balloon Dilatation Catheter, which recently received CE mark approval. The device is a low profile .014 inch rapid exchange (Rx) system that offers physicians procedural speed and efficiency when performing angioplasty procedures on patients with carotid or renal artery disease.

In addition, Cordis will showcase the FIRE STAR™ Rx PTCA (Percutaneous Transluminal Coronary Angioplasty) Dilatation Catheter, which offers the lowest pre-dilatation balloon profile in the market for patients with coronary artery disease and the DURA STAR™ Rx PTCA Dilatation Catheter, which facilitates the post-delivery expansion of stents in coronary arteries and is suitable for tackling tortuous anatomy and calcified lesions. Both products were recently launched in Europe.

Professional Education

In the educational front, the Cordis® Cardiac & Vascular Institute™, started by Cordis in 2006 to advance professional medical education, will hold two symposia and seven case review sessions.

Following please find the schedule of key Cordis-related events:


1:30 p.m. Central European Summer Time (CEST)

Symposium -- Endovascular Treatment of Lower Limbs

Room 2

Clinical investigators will discuss multidisciplinary approaches in the selection and treatment of patients with peripheral arterial disease, including current technologies for crossing complex chronic total occlusions in the lower limb. They will also present preliminary data at 36 and 48 months from the SIROCCO II Trial.

3 p.m. CEST

Case Review Session -- Challenges in Treating Long Coronary Lesions

Room 120-121

4:30 p.m. CEST

Case Review Session -- Planning Your Strategies in Treating Multivessel Coronary Disease

Room 120-121

5:40 p.m. CEST

Late Breaking Clinical Trial -- ARTS II Study at Three Years: Diabetic Subset Analysis

Main Arena

Keith Dawkins, M.D., F.R.C.P., F.A.C.C., of Southampton University Hospital, England, will present three-year follow-up data from the ARTS II Study. The presentation will include a subgroup analysis assessing outcomes in diabetic patients.


12 p.m. CEST

Case Review Session -- Coronary In-stent Restenosis: The Achilles Heel Is Back

Room 120-121

4:30 p.m. CEST

Case Review Session -- Techniques for Challenging Cases in Carotid Stenting

Room 120-121

4:30 p.m. CEST

Case review session -- Left Main Bifurcation Lesions: Advanced Strategies and Long-term Angiographic Follow-up

Room 6


12 p.m. CEST

Case Review Session -- Adapting Your Strategies to the Challenging Coronary Anatomy of Diabetic Patients

Room 120-121

4:30 p.m. CEST

Symposium -- Optimising Safety and Efficacy in Coronary Drug-eluting Stent Procedures

Main Arena

Distinguished faculty speakers from across Europe will discuss how to optimize the safety and efficacy of angioplasty procedures with drug-eluting stents. Topics of discussion include the impact of restenosis and patient selection in clinical outcomes, as well as the CYPHER® Stent safety and efficacy data.

4:30 p.m. CEST

Case Review Session -- Coronary Chronic Total Occlusions

Room 120-121


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.